Friday, July 4, 2025 7/4/2025

Contribution of the Inflammasome to Radiation Response in Pancreatic Cancer

Award Number: K22CA251643
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 02/01/2022
PERIOD OF PERFORMANCE END DATE: 01/31/2025

Group Awards By:

View Award Description

Contribution of the Inflammasome to Radiation Response in Pancreatic Cancer - PROJECT SUMMARY/ABSTRACT The central theme of my postdoctoral fellowships has been to investigate mechanisms by which myeloid cells are recruited and activated to promote inflammation and immunosuppression during cancer. Chronic inflammation is a recognized hallmark of carcinogenesis and my research focus is to identify critical inflammatory pathways for combinatorial therapeutic strategies, such that the immune system can be harnessed for antitumor immunity. My current research focus is on pancreatic cancer, which is largely resistant to chemotherapy, radiation therapy (RT), and immune checkpoint blockade. RT elicits an immunogenic cell death whereby resident and recruited leukocytes respond to damage-associated molecular patterns (DAMPs) released by dying cells. Macrophages are central mediators of this response and recognize DAMPs via innate adjuvant sensors, including the toll-like receptor (TLR)/MyD88 pathway. Specificity in this pathway is regulated by expression of various NFB subunits that homo- or heterodimerize to drive transcriptional pathways involved in immune activation or immune suppression. My current work is to understand how Mertk-dependent upregulation of NFB p50 regulates macrophage immune suppression post-RT, and suppresses local antitumor immunity by rewiring macrophage response to adjuvant signals through MyD88 signaling. This proposal extends on these findings to test the central hypothesis that inflammasome activation in tumor- associated macrophages restricts RT-induced antitumor CD8+ T cell responses in pancreatic cancer. As the first step of inflammasome activation, MyD88 signaling regulates transcription of IL1 and IL18 while the second step involves additional activation of inflammasome receptors by factors released by dying cells in response to RT. Our preliminary data implicate inflammasome activation in macrophages as a critical mechanism regulating immunosuppression following RT. Thus, we aim to (1) determine the functional significance of inflammasome activation in RT-mediated tumor clearance and (2) identify inflammasome signatures and phenotypes in macrophages responding to RT and determine whether this signature correlates with poor outcomes in patients. Studies utilizing lineage-specific knockout mice will identify the cell types in which inflammasome activation occurs and its functional consequences on regulating CD8+ T cell responses in response to RT. My long-term career goal is to become an independent investigator studying dominant immune mechanisms regulating cancer development and how certain aspects of innate immunity impart barriers to effective therapeutic strategies, including both traditional cytotoxic and immune-based therapies. During the K22 award period I plan to gain additional training to expand my skill set in bioinformatics, statistics, lab management, and communication skills, and to develop my independent research program so that I may establish a record of independent research project grant program funding.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	PROVIDENCE HEALTH & SERVICES - OREGON	4805 NE GLISAN ST	PORTLAND	OR	97213	MULTNOMAH	USA	Cancer Research Manpower	000	3	5/19/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $162,000 )
2024	2024	PROVIDENCE HEALTH & SERVICES - OREGON	4805 NE GLISAN ST	PORTLAND	OR	97213	MULTNOMAH	USA	Cancer Research Manpower	000	3	2/2/2024	NON-COMPETING CONTINUATION	$162,000
														Subtotal = $162,000

Issue Date FY: 2023 ( Subtotal = $162,000 )
2023	2023	PROVIDENCE HEALTH & SERVICES - OREGON	4805 NE GLISAN ST	PORTLAND	OR	97213	MULTNOMAH	USA	Cancer Research Manpower	000	2	12/22/2022	NON-COMPETING CONTINUATION	$162,000
														Subtotal = $162,000

Issue Date FY: 2022 ( Subtotal = $162,000 )
2022	2022	PROVIDENCE HEALTH & SERVICES - OREGON	4805 NE GLISAN ST	PORTLAND	OR	97213	MULTNOMAH	USA	Cancer Research Manpower	000	1	2/1/2022	NEW	$162,000
														Subtotal = $162,000

Grand Total All Awards = $486,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Contribution of the Inflammasome to Radiation Response in Pancreatic Cancer

Award Number: K22CA251643

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 02/01/2022

PERIOD OF PERFORMANCE END DATE: 01/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer